Abstract
Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Srigley JR, Eble JN (1998) Collecting duct carcinoma of kidney. Semin Diagn Pathol 15:54–67
Gollob JA, Upton MP, DeWolf WC et al (2001) Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology 58:1058
Milowsky MI, Rosmarin A, Tickoo SK et al (2002) Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature. Cancer 94:111–116
Peyromaure M, Thiounn N, Scotté F et al (2003) Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol 170:1138–1140
Tokuda N, Naito S, Matsuzaki O et al (2006) Collecting duct (Bellini duct) renal cell carcinoma: a nationwide survey in Japan. J Urol 176:40–43
Oudard S, Banu E, Vieillefond A et al (2007) Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol 177:1698–1702
Chao D, Zisman A, Pantuck AJ (2002) Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol 167:71–74
Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 26:543–549
Choueiri TK, Plantade A, Elson P et al (2008) Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 26:127–131
Ansari J, Fatima A, Chaudhri S et al (2009) Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney. Onkologie 32:44–46
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Miyake, H., Haraguchi, T., Takenaka, A. et al. Metastatic collecting duct carcinoma of the kidney responded to sunitinib. Int J Clin Oncol 16, 153–155 (2011). https://doi.org/10.1007/s10147-010-0116-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-010-0116-z